MAR 28·MarketBeat→
Avanos Medical (NYSE:AVNS) Rating Increased to Buy at Wall Street Zen
Wall Street Zen has upgraded Avanos Medical (NYSE:AVNS) from a "hold" to a "buy" rating, although MarketBeat's consensus remains "Reduce" due to mixed analyst opinions. The company surpassed Q4 earnings estimates with EPS of $0.29 and revenue of $180.9M, and institutional investors now hold approximately 95.17% of the stock. Despite a negative net margin of -10.40%, Avanos Medical reported a positive ROE of 5.47% and provided FY2026 EPS guidance between $0.90–1.10.
MAR 22·Intellectia AI→
AVNS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Avanos Medical Inc (AVNS), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's primary revenue driver is Digestive Health, contributing 65.9% of total sales. While AVNS maintains a gross margin of 47.54%, its net margin is negative at -0.72%, with a Return on Equity of -9.07%.
